Earnings summaries and quarterly performance for CNS Pharmaceuticals.
Executive leadership at CNS Pharmaceuticals.
Board of directors at CNS Pharmaceuticals.
Research analysts covering CNS Pharmaceuticals.
Recent press releases and 8-K filings for CNSP.
CNS Pharmaceuticals, Inc. Stockholders Approve Significant Increase in Authorized Shares and Equity Plan Amendments
CNSP
Proxy Vote Outcomes
Executive Compensation
Board Change
- At its Annual Meeting on November 17, 2025, CNS Pharmaceuticals, Inc. stockholders approved an amendment to the company's Amended and Restated Articles of Incorporation to increase the total number of authorized shares of common stock from 25,000,000 to 300,000,000 shares and preferred stock from 416,667 to 5,000,000 shares.
- Stockholders also approved amendments to the 2020 Equity Plan, which included an increase in the number of common stock shares authorized for issuance under the plan by 114,916, bringing the new total to 115,061 shares available for issuance.
- The company filed the Certificate of Amendment to its Amended and Restated Articles of Incorporation with the Nevada Secretary of State on November 20, 2025.
- Additionally, at the Annual Meeting, stockholders elected six directors and ratified MaloneBailey, LLP as the independent registered public accounting firm for the year ending December 31, 2025.
Nov 21, 2025, 10:19 PM
Quarterly earnings call transcripts for CNS Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more